German drugmaker CureVac and GSK reached an agreement with BioNTech and Pfizer on Thursday to resolve a years-long patent ...

In Danes over age 65, the vaccine effectiveness of the JN.1-based mRNA boosters reached 70-85% against COVID-related hospitalization and 76-96% against COVID-associated death. Despite the shift away ...

CureVac said on Thursday that the company and GSK have entered an agreement to a resolve patent dispute with Pfizer and ...

Messenger RNA vaccines, or mRNA, differ from traditional ones. Instead of growing a virus and weakening it to allow the body to engage its natural defenses, mRNA vaccines use pieces of genetic code to ...

A research project at Emory University is among the 22 grants and contracts that are being cancelled as the U.S. Department ...

In justifying the government's termination of $500 million in funding for mRNA vaccine projects, Health and Human Services ...

Jerome Adams, the U.S. Surgeon General under President Trump's first term, is criticizing his administration's cuts to mRNA ...

Warning comes after HHS Secretary Robert F. Kennedy Jr. announced cuts of nearly $500m in funding for mRNA vaccine projects, ...

Modern science emerged precisely to deal with the way everything can be manipulated – and scepticism over ‘facts’ goes all ...

Federal vaccine policy changes under RFK Jr. have some concerned health insurance will not cover COVID shots. A bill in NY seeks to mandate coverage.

Pfizer Inc (($PFE)) announced an update on their ongoing clinical study. Pfizer Inc. is conducting a study titled ‘Estimated Vaccine Effectiveness ...

Detailed price information for Arbutus Biopharma Corp (ABUS-Q) from The Globe and Mail including charting and trades.